Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Mary Lynne Hedley, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan, while also reporting indirect ownership of 98 shares held in a trust.

Summary

• Mary Lynne Hedley, a director at Eli Lilly & Co, has reported a transaction involving the company's common stock.
• On May 20, 2024, Ms. Hedley acquired 13 shares of common stock at a price of $783.18 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, where stock units are granted in lieu of cash compensation and will be settled in shares after her separation from service.
• Ms. Hedley also reported indirect ownership of 98 shares of common stock held by a trust.
• She disclaims beneficial ownership of these trust-held securities except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a positive alignment of interests between the director and the company, but it is not a major event.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of a deferral plan aligns the director's interests with the long-term performance of the company.

Industry Context

This filing is a routine disclosure of a director's stock transaction, which is common in publicly traded companies. It reflects the compensation practices and alignment of interests between management and shareholders.

Comparison to Industry Standards

• Director stock acquisitions are a common practice across the pharmaceutical industry, often as part of compensation packages.
• Many companies use deferral plans to align director interests with long-term company performance, similar to Eli Lilly's approach.
• The reporting of indirect ownership through trusts is also standard practice for corporate insiders.

Stakeholder Impact

• The stock acquisition by a director can be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Eli Lilly, Director, Stock Acquisition, Deferral Plan, Beneficial Ownership, Common Stock, SEC Form 4